Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. - Wikidata - awgldk - TriplyDB

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

http://www.wikidata.org/entity/Q33990908

about

Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Clinical application of genetics to guide prevention and treatment of oral diseases Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Oral epithelial stem cells - implications in normal development and cancer metastasis.Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.Future directions and treatment strategies for head and neck squamous cell carcinomas Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Systemic therapy strategies for head-neck carcinomas: Current status Inherent phenotypic plasticity facilitates progression of head and neck cancer: endotheliod characteristics enable angiogenesis and invasion Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420 Molecular characterization of head and neck cancer: how close to personalized targeted therapy?Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Management of recurrent head and neck cancer: recent progress and future directions.Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.Angiogenesis in head and neck cancer: a review of the literature.Novel targeted therapies in head and neck cancer.Novel targets for VEGF-independent anti-angiogenic drugs.Targeted therapy in head and neck cancer.The role of antiangiogenic agents in the treatment of head and neck cancer.Autophagic action of new targeting agents in head and neck oncology.Promising new molecular targeted therapies in head and neck cancer.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Emerging tyrosine kinase inhibitors for head and neck cancer.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.Palliative treatment standards for head and neck squamous cell carcinoma : Survey of clinical routine in German-speaking countries.Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.Biologic therapy in head and neck cancer: a road with hurdles.Emerging drugs for head and neck cancer.Precision Therapy of Head and Neck Squamous Cell Carcinoma.Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.

P2860

Q26765429-2022439E-2866-4D2E-8178-FDB532477123 Q26999507-7AB85297-6820-4268-ABCB-F100471F7AC9 Q27003304-1F4A7C0E-F46D-47DD-8FCB-09E80BB7A8A4 Q33401136-4DB96FFC-640D-4956-920B-ED0E7DC6A5A0 Q34147649-11727300-DC20-448F-9622-77CE226D4B1D Q34163076-ADB4507F-181B-4B26-8453-50A6BCB6492B Q35693308-C3F97E06-5DC7-45D3-9E67-500F8F6D4A3E Q35703167-F8398133-7C60-46E2-B629-BD456ECE703E Q36177257-84C4177F-F736-4DC1-B252-E59ADD01E8D9 Q36270115-71BCFCC0-6809-4AB6-A897-4296A9DE8402 Q36529843-7EA56912-BC83-4A0F-B019-C187F34147F0 Q36698965-19ECC4D0-9012-4E95-8705-2DC4FA3B3430 Q36960552-B9CA1458-791A-481E-AE42-876535AB29C7 Q37000422-B977D928-198E-4938-AA44-3AA42AAEA477 Q37328494-2DBF270A-91E4-4AED-B57E-55CDA402F2CE Q37921278-CED7CF0D-F29A-49A6-BD66-C6E9F153C40D Q37952659-7BE8A5E3-D7BC-4914-8F2E-8A3B5FA4543B Q37963379-4E7D1313-918C-45DC-A345-291B2257445E Q37975224-8CD53AC5-6B4D-4454-835F-B038267160CF Q37984612-BF676213-ABD8-45B2-8FBD-FF51D1FB85CA Q37988981-8E1FF7B5-749F-4245-AE69-EE463784A7C8 Q38025003-AD0328C0-C2A8-4DDC-BA4C-730E2868DD38 Q38028794-B16F2C6C-2365-43C9-AC46-34F5BAFD486B Q38084617-237C9D44-6124-44EE-BEB0-7E89D7C01298 Q38103397-CBB0F34E-BC5C-478D-9476-E38727785569 Q38149327-55B9B39E-08F8-4273-8BE1-6A6C5EADC3E6 Q38838071-B8116CFF-A3AC-4124-A125-E7746D795834 Q38855031-02BE71CF-ABC8-4D0D-BC1C-48D13F8433CE Q39297056-3648D3FE-A991-4C56-8BA7-BA8E3A57C18C Q39684719-05F162EE-3F33-4109-AC94-41D84F354CD8 Q41133695-A686ECC3-159B-442F-8CF1-FD165435270A Q41239578-D2DF0D0D-6793-46DC-BCBE-26D6F0B8996B Q42213295-B51306BB-385A-47D7-A35C-694FD0F1AE10 Q45874449-F8E88975-9161-49B2-BA46-07AF6F0F97B1 Q52591781-E7410B87-23CA-4DEE-8F7B-4FCB7003C77D Q55476332-4162FAD3-E9FA-4A33-9BF5-ABBCD4317E63

P2860

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

http://www.wikidata.org/entity/Q33990908

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@ast

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@en

type

label

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@ast

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@en

prefLabel

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@ast

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@en

P1433

Q33990908-F91A8C22-75A5-4551-8A42-09BDD6D78C3E

P1476

Q33990908-64D59099-D58B-4048-9630-CE294A3ABB14

P2093

Q33990908-210FE280-C35D-4EB3-A0C1-BB217D324A55

Q33990908-28192117-5928-4A61-9E26-5C7DFD0A2982

Q33990908-51E76E62-128D-47A2-9F71-CBBD383DD6B3

Q33990908-57963F1E-798E-4A50-A125-A87E0D2BE659

Q33990908-630704DA-2270-4BA4-9CDE-7A2D6FA53C12

Q33990908-D40FF638-3587-4146-9664-6293CD22C133

Q33990908-FD327A1E-AD0E-4F12-B506-832C0150FF6F

P2860

Q33990908-04DBEA06-1F28-4FD6-A07C-DB591083C4EA

Q33990908-1AEBCB0C-20FE-4BD0-BF28-FAD4CB900CE1

Q33990908-25687E78-0455-4FFF-91D1-EEE312D57858

Q33990908-283B090F-3773-46FE-85FB-CA327AEE43D7

Q33990908-2D6BE489-B9A6-4EB8-9427-A381A9AF811E

Q33990908-2F35091D-5315-4C11-BA51-024B654EC25E

Q33990908-2FABD9CB-FDC6-4611-A955-1225FBF6865F

Q33990908-307D79B3-EDAB-4532-B2F4-95208BCC37D8

Q33990908-3A65497C-6121-4483-8659-AD88F3034DD4

Q33990908-51405FAA-83E0-4A43-8BF1-6FD35F69023E

P304

Q33990908-110E82E9-8F31-460B-90EA-F6AD3079D814

P31

Q33990908-1ADE7895-AEF4-4287-A722-E9D32D743783

P356

Q33990908-75B70722-91F5-4EEE-AE31-95326EC06B72

P407

Q33990908-13309CF9-5B99-4A7F-9A8B-DE9BE5653279

P433

Q33990908-7F95A7A8-6171-4EE7-AFC1-8BC8CD8BCB0E

P478

Q33990908-3F3A707E-1597-44D8-9F76-17FE307625A2

P577

Q33990908-EB45B4DE-C834-42D5-A7AD-AD440CBDD974

P698

Q33990908-29A12045-48C7-4693-8133-09F3D0995C40

P932

Q33990908-F31AD350-DBF3-4104-AE2A-EC34A26AEE4C

P356

JCO.2009.25.6834

P1433

Journal of Clinical Oncology

P1476

Phase II evaluation of sorafen ...... st Oncology Group Study S0420.

@en

P2093

Chao H Huang

http://www.w3.org/2001/XMLSchema#string

Gregory T Wolf

http://www.w3.org/2001/XMLSchema#string

James Moon

http://www.w3.org/2001/XMLSchema#string

Michael LeBlanc

http://www.w3.org/2001/XMLSchema#string

Perry P Guaglianone

http://www.w3.org/2001/XMLSchema#string

Stephen K Williamson

http://www.w3.org/2001/XMLSchema#string

Susan G Urba

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Mechanisms of regulating the Raf kinase family

Sorafenib in advanced clear-cell renal-cell carcinoma

Epidermal growth factor-related peptides and their receptors in human malignancies

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.

P304

3330-3335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.6834

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20498388

http://www.w3.org/2001/XMLSchema#string

P932

2903329

http://www.w3.org/2001/XMLSchema#string